OpenLB
Open Library of Bioscience
Advanced Search
Scientific reports
09 07, 2017;7 (1): 10830.

Biological effects of dosing aerobic exercise and neuromuscular electrical stimulation in rats.

Stefania Dalise, Loredana Cavalli, Harmanvir Ghuman, Brendon Wahlberg, Madeline Gerwig, Carmelo Chisari, Fabrisia Ambrosio, Michel Modo
Author Information
  1. Stefania Dalise: University of Pittsburgh, McGowan Institute for Regenerative Medicine, Pittsburgh, Pennsylvania, USA. ORCID
  2. Loredana Cavalli: University of Pittsburgh, McGowan Institute for Regenerative Medicine, Pittsburgh, Pennsylvania, USA. ORCID
  3. Harmanvir Ghuman: University of Pittsburgh, McGowan Institute for Regenerative Medicine, Pittsburgh, Pennsylvania, USA.
  4. Brendon Wahlberg: Department of Radiology, Pittsburgh, Pennsylvania, USA.
  5. Madeline Gerwig: Department of Neuroscience, Pittsburgh, Pennsylvania, USA.
  6. Carmelo Chisari: University Hospital of Pisa, Department of Neuroscience, Unit of Neurorehabilitation, Pisa, Italy.
  7. Fabrisia Ambrosio: University of Pittsburgh, McGowan Institute for Regenerative Medicine, Pittsburgh, Pennsylvania, USA.
  8. Michel Modo: University of Pittsburgh, McGowan Institute for Regenerative Medicine, Pittsburgh, Pennsylvania, USA. mmm154@pitt.edu. ORCID
PMID: 28883534 DOI: 10.1038/s41598-017-11260-7

Abstract

Aerobic exercise (AE) and non-aerobic neuromuscular electric stimulation (NMES) are common interventions used in physical therapy. We explored the dose-dependency (low, medium, high) of these interventions on biochemical factors, such as brain derived neurotrophic growth factor (BDNF), vascular endothelial growth factor-A (VEGF-A), insulin-like growth factor-1 (IGF-1) and Klotho, in the blood and brain of normal rats, as well as a treadmill-based maximum capacity test (MCT). A medium dose of AE produced the most improvement in MCT with dose-dependent changes in Klotho in the blood. A dose-dependent increase of BDNF was evident following completion of an NMES protocol, but there was no improvement in MCT performance. Gene expression in the hippocampus was increased after both AE and NMES, with IGF-1 being a signaling molecule that correlated with MCT performance in the AE conditions, but also highly correlated with VEGF-A and Klotho. Blood Klotho levels can serve as a biomarker of therapeutic dosing of AE, whereas IGF-1 is a key molecule coupled to gene expression of other molecules in the hippocampus. This approach provides a translatable paradigm to investigate the mode and mechanism of action of interventions employed in physical therapy that can improve our understanding of how these factors change under pathological conditions.

References

  1. Cardiopulm Phys Ther J. 2012 Jun;23(2):19-29 [PMID: 22833706]
  2. Neural Plast. 2016;2016:2961573 [PMID: 26881101]
  3. Braz J Biol. 2014 May;74(2):444-9 [PMID: 25166329]
  4. Stroke. 2015 Aug;46(8):2197-205 [PMID: 26173724]
  5. Neural Plast. 2017;2017:2350137 [PMID: 28191352]
  6. Stem Cells. 2012 Apr;30(4):785-96 [PMID: 22213183]
  7. Front Neurol. 2011 May 06;2:28 [PMID: 21602910]
  8. Neurorehabil Neural Repair. 2011 Oct;25(8):740-8 [PMID: 21705652]
  9. Curr Atheroscler Rep. 2013 Jun;15(6):331 [PMID: 23591673]
  10. Circulation. 2014 Jul 1;130(1):69-78 [PMID: 24982118]
  11. Phys Med Rehabil Clin N Am. 2014 Aug;25(3):631-54, ix [PMID: 25064792]
  12. Cardiol Clin. 2016 Nov;34(4):603-608 [PMID: 27692228]
  13. J Neurol Neurosurg Psychiatry. 2003 Nov;74(11):1562-6 [PMID: 14617717]
  14. Med Sci Sports. 1979 Winter;11(4):338-44 [PMID: 530025]
  15. J Physiol Pharmacol. 2010 Oct;61(5):533-41 [PMID: 21081796]
  16. Muscle Nerve. 2017 Feb;55(2):179-189 [PMID: 27313001]
  17. Cleve Clin J Med. 2017 Feb;84(2):161-168 [PMID: 28198688]
  18. Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20575-82 [PMID: 19106295]
  19. Transl Psychiatry. 2017 Jan 31;7(1):e1017 [PMID: 28140399]
  20. Autoimmun Rev. 2013 Apr;12(6):674-7 [PMID: 23201925]
  21. BMJ Case Rep. 2011 Oct 11;2011:null [PMID: 22675006]
  22. Sports Med. 2017 Mar;47(Suppl 1):65-78 [PMID: 28332113]
  23. Arch Phys Med Rehabil. 2013 Jan;94(1 Suppl):S55-60 [PMID: 23168302]
  24. J Strength Cond Res. 2013 Jan;27(1):208-15 [PMID: 23254490]
  25. Compr Physiol. 2013 Jan;3(1):121-39 [PMID: 23720282]
  26. J Vis Exp. 2012 May 09;(63):e3914 [PMID: 22617846]
  27. PLoS One. 2013;8(3):e54922 [PMID: 23526927]
  28. Lab Anim. 2006 Jul;40(3):261-74 [PMID: 16803643]
  29. In Vivo. 2010 Nov-Dec;24(6):827-36 [PMID: 21164040]
  30. Nephrourol Mon. 2016 Jan 09;8(1):e30245 [PMID: 26981496]
  31. J Clin Endocrinol Metab. 2010 Nov;95(11):E352-7 [PMID: 20685863]
  32. Front Neurol. 2015 Aug 26;6:187 [PMID: 26379621]
  33. Neurorehabil Neural Repair. 2012 Oct;26(8):923-31 [PMID: 22466792]
  34. J Neurosci Methods. 2008 Jan 30;167(2):317-26 [PMID: 17870182]
  35. J Neurosci. 2001 Mar 1;21(5):1628-34 [PMID: 11222653]
  36. Free Radic Biol Med. 2007 Sep 15;43(6):901-10 [PMID: 17697935]
  37. Neuroimage. 2016 May 1;131:142-54 [PMID: 26545456]
  38. Physiol Behav. 2015 Mar 1;140:8-14 [PMID: 25479573]
  39. Alzheimers Dement. 2007 Apr;3(2 Suppl):S30-7 [PMID: 19595972]
  40. Curr Opin Neurol. 2012 Dec;25(6):676-81 [PMID: 23041959]
  41. Eur J Neurosci. 2016 Feb;43(3):336-50 [PMID: 26121368]
  42. Front Psychol. 2012 Mar 23;3:86 [PMID: 22470361]
  43. J Anim Sci. 2007 Jan;85(1):163-71 [PMID: 17179552]
  44. Med Sci Sports Exerc. 2013 Mar;45(3):420-8 [PMID: 23034644]
  45. Lab Anim. 2006 Oct;40(4):371-81 [PMID: 17018208]
  46. Clin Biochem. 2014 Jul;47(10-11):876-88 [PMID: 24486649]
  47. J Appl Physiol (1985). 2005 Dec;99(6):2307-11 [PMID: 16081619]
  48. Cardiovasc Diabetol. 2007 Dec 13;6:38 [PMID: 18078520]
  49. Top Stroke Rehabil. 2012 Nov-Dec;19(6):491-8 [PMID: 23192714]
  50. Clin Interv Aging. 2015 Aug 04;10:1233-43 [PMID: 26346243]
  51. J Neurosci. 2001 Aug 1;21(15):5678-84 [PMID: 11466439]
  52. Nutr Hosp. 2015 Feb 26;31 Suppl 3:237-44 [PMID: 25719791]
  53. Oncogene. 2008 Nov 27;27(56):7094-105 [PMID: 18762812]
  54. Ann Anat. 2011 Jul;193(4):354-61 [PMID: 21498059]
  55. Pediatr Phys Ther. 2013 Fall;25(3):257-70 [PMID: 23743574]
  56. Am J Physiol Heart Circ Physiol. 2014 Feb;306(3):H348-55 [PMID: 24322608]
  57. Neurotox Res. 2012 May;21(4):418-34 [PMID: 22183422]
  58. Acta Physiol Hung. 2013 Dec;100(4):427-34 [PMID: 24013943]
  59. Front Physiol. 2014 Jun 17;5:189 [PMID: 24987372]
  60. J Clin Invest. 1949 Nov;28(6 Pt 2):1423-30 [PMID: 15407661]
  61. Circulation. 2016 Jun 7;133(23 ):2297-313 [PMID: 27267537]
  62. Br J Sports Med. 2017 Mar;51(6):549-550 [PMID: 27251899]
  63. Lab Anim. 2014 Oct;48(4):278-91 [PMID: 24958546]
  64. Trends Neurosci. 2007 Sep;30(9):464-72 [PMID: 17765329]
  65. Front Neuroendocrinol. 2017 Jul;46:86-105 [PMID: 28614695]
  66. Psychopharmacology (Berl). 2014 Jul;231(13):2661-70 [PMID: 24464528]

Grants

  1. P2C HD086843/NICHD NIH HHS
  2. R56 AG052978/NIA NIH HHS

MeSH Term

Animals
Biomarkers
Brain-Derived Neurotrophic Factor
Electric Stimulation
Exercise Test
Gene Expression Regulation
Hippocampus
Male
Motor Activity
Peripheral Nervous System
Physical Conditioning, Animal
Psychomotor Performance
RNA, Messenger
Rats

Chemicals

Biomarkers
Brain-Derived Neurotrophic Factor
RNA, Messenger
brain-derived growth factor
Journal Article Research Support, N.I.H., Extramural
Article has an altmetric score of 3

Word Cloud

Created with Highcharts 10.0.0AEKlothoMCTNMESinterventionsgrowthIGF-1exerciseneuromuscularstimulationphysicaltherapymediumfactorsbrainBDNFVEGF-Abloodratsimprovementdose-dependentperformanceexpressionhippocampusmoleculecorrelatedconditionscandosingAerobicnon-aerobicelectriccommonusedexploreddose-dependencylowhighbiochemicalderivedneurotrophicfactorvascularendothelialfactor-Ainsulin-likefactor-1normalwelltreadmill-basedmaximumcapacitytestdoseproducedchangesincreaseevidentfollowingcompletionprotocolGeneincreasedsignalingalsohighlyBloodlevelsservebiomarkertherapeuticwhereaskeycoupledgenemoleculesapproachprovidestranslatableparadigminvestigatemodemechanismactionemployedimproveunderstandingchangepathologicalBiologicaleffectsaerobicelectrical

Similar Articles

Cited By